Chimeric antigen receptor therapy for hepatocellular carcinoma
Seminars in Immunology · 2026
DOI: 10.1016/j.smim.2025.102000 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Immunology, 2026. Verfasst von Lorenz Kocheise und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institute…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, German Research Foundation, National Institutes of Health.
Abstract (Originalsprache)
Adapting the success of chimeric antigen receptor T cell therapy from hematologic malignancies to solid tumors has become a major focus of ongoing research activities. However, the unique challenges posed by solid tumors, such as limited immune cell infiltration, reduced T cell persistence, and antigen loss, have led to only limited success in early clinical trials. Recently, combinatorial strategies incorporating next-generation armored CAR T cells along with various alternative immune cell types have rekindled optimism in the field. Hepatocellular carcinoma represents a distinct entity due to the unique characteristics of the liver microenvironment, including the influence of lipid metabolism, bile acids, and microbial compounds from the gut-liver axis. Furthermore, HCC is characterized by a variety of tumor-specific and tumor-associated antigens, enabling targeted approaches with minimal risk of on-target/off-tumor effects. The unique complexity of HCC, along with the underlying liver diseases that give rise to these tumors, presents both challenges and opportunities for cellular therapies. In this review, we examine the current landscape of CAR T cell therapy for HCC, highlighting recent clinical and preclinical developments. Furthermore, we discuss why HCC may be especially well-suited for tailored CAR-based strategies, given the liver's specific anatomical and immunological properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Antibody Engineering Program, Center for Cancer Research, National Cancer Institu…
- Gastrointestinal Malignancies Section, Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Liver Cancer Program, Center for Cance…
Förderung
- Intramural NIH HHS
- German Research Foundation
- National Institutes of Health
- National Cancer Institute
Zitieren
APA
Kocheise, L., Benmebarek, M. R., Ho, M., & Greten, T. F. (2026). Chimeric antigen receptor therapy for hepatocellular carcinoma. Seminars in Immunology. https://doi.org/10.1016/j.smim.2025.102000
Vancouver
Kocheise L, Benmebarek MR, Ho M, Greten TF. Chimeric antigen receptor therapy for hepatocellular carcinoma. Seminars in Immunology. 2026. doi:10.1016/j.smim.2025.102000
BibTeX
@article{Kocheise2026,
author = {Kocheise, Lorenz and Benmebarek, Mohamed-Reda and Ho, Mitchell and Greten, Tim F},
title = {Chimeric antigen receptor therapy for hepatocellular carcinoma},
journal = {Seminars in Immunology},
year = {2026},
doi = {10.1016/j.smim.2025.102000}
}
EUVIMED